Why the Standard Life model could go European

Anyone watching the UK bulk annuity market has been turning over the Standard Life carve-out for the past few weeks (I know, this is a mass appeal article). Gordon Aitken’s piece on it is the place to start, and his earlier note on private capital moving into UK bulk annuities frames the wider context. Aitken’s analytical work is more thorough than mine. He gets the structure right (partly-owned subsidiary, consortium equity drip-fed alongside new business), draws the right parallel to Apollo’s ACRA sidecar at Athene, and works through the equity-shareholder question of whether the listed market gains or loses. I will not retrace any of it.

But there is another reading of the deal that I’ve been thinking about over the weekend. Read against my post last week - the five-thoughts piece - this is not really a corporate engineering story. I think the Standard Life structure may be the first visible example of an emerging UK regulatory architecture that simultaneously satisfies prudential supervision and growth-policy goals. Because it goes after both of these, I suspect it might be quite durable, and it might look very tempting to European governments and regulators as well.

Two government objectives, one framework

The PRA’s framework for alternative life capital is mainly about prudential supervision and policyholder protection. Keep capital onshore, keep the regulated entity under PRA oversight, make sure the assets backing UK annuities sit inside the UK regulatory perimeter, not in Bermuda. The lesson from the BaFin / Viridium episode is that European regulators are uncomfortable with pure private-equity control of a life consolidator unless there is a sufficiently trusted long-term owner standing behind it. Eurovita is not the same fact pattern, but it made this backstop question very visible (and I’ve learned about the ‘reference shareholder’ concept in that past few years). The prudential argument holds together.

What the framework also delivers, almost as a very happy coincidence, is something HM Treasury has been pushing for years. The Mansion House Compact had life insurers pledge £100bn of UK productive investment over a decade. The Mansion House Accord aimed to double DC pension allocations to private markets to 10%, with half ring-fenced for UK assets. Solvency UK reforms, the matching adjustment changes, the MAIA framework, the funded-re consultation: every one of them targets UK productive investment as an objective. HMT, the PRA and the industry coordinate explicitly through the ABI’s Investment Viability Group. The objective is not hidden.

So when the PRA tightens the offshore funded-re route and consults on opening up onshore alternative life capital structures, two policy goals get met at once. Prudential supervision improve, and the regulated entity stays inside the PRA’s perimeter. Growth policy improves at the margin, and more of the capital stack and asset-origination activity remains inside the UK, where it can support productive-finance objectives.

I am not suggesting any of this is a conspiracy! The PRA has not compromised its prudential mandate to serve Treasury’s growth one. But there is a very public political tailwind that has helped onshore alternative life capital more than the prudential logic alone would deliver, and that matters. As we’ve all seen in the past decade or so, politicians love tinkering with the rules - but in this case, the framework is harder to change, because the cost of change hits both PRA and HMT objectives.

Does it travel?

Honestly, I am not sure. The obvious candidates are not obvious candidates.

The big continental composites (Allianz, AXA, Generali, Zurich) are not in the UK’s position. They are diversified P&C plus life plus asset management businesses where the life book is one of several engines. Their listed valuations reflect that. Allianz is trading near all-time highs in 2026. AXA, Generali and Zurich are all well credited. They do not face the persistent listed-market discount that UK life-only insurers do, and they have less reason to bring in third-party capital to write new long-duration business. They are also on the buy side of European consolidation. Allianz, for instance, joined the consortium that took Viridium from Cinven. The Standard Life model is a solution to a problem that doesn’t obviously exist in these cases.

Closed-book consolidation and the smaller continental new-business BPA markets do look more similar to the UK. The Eurovita collapse showed European regulators what happens when pure PE owns a consolidator and is unwilling to backstop it in stress. BaFin’s rejection of Cinven’s ownership of Viridium showed what happens next. The Standard Life model, with the regulated entity inside a stable parent and private capital as equity sponsor of a ring-fenced subsidiary, is a structure that addresses what European regulators have already said they object to. Whether BaFin, the ACPR, IVASS or DNB explicitly encourage variants is a question for them, but there’s now a pretty clear template.

The political-economy alignment travels too, but unevenly. 15 or so years ago a few colleagues and I wrote a piece about how regulation travels from the UK throughout the world, and I think the core logic still holds. France has Mansion House-equivalent ambitions for domestic investment, but a different regulatory culture. Germany has the supervisory infrastructure but a less explicit growth-policy push around insurance capital. Italy has the post-Eurovita motivation but a smaller BPA market to apply it to. Each jurisdiction is a different mix of regulatory motivation, political appetite, and structural conditions in its life sector. Some combinations might favour Standard Life-style structures, but others will not. (yes, I’m aware that sounds very consultant-y)

The bigger barrier may not be appetite but plumbing. The UK has a large BPA market, a matching-adjustment regime, listed insurers with capital-strain problems, and a government explicitly trying to mobilise domestic long-term capital. Other jurisdictions may share one or two of those features, but I can’t think of many that share all four. Tax, accounting, group-capital fungibility, asset eligibility, ring-fencing and minority-investor protections all have to work locally before the model can be lifted across. Regulatory appetite is necessary but not sufficient.

What I will be bolder about is the smaller claim. The UK has built the first credible example of a regulatory architecture that addresses the main Viridium issue while also serving a growth-policy objective. Other European governments facing anything like the same combination of pressures now have a worked example to point to, and historically ideas that help political agendas tend to travel.

How the UK model actually works

The structure itself is not new. Life and annuity sidecars have existed in the US and Bermuda since Apollo set up ACRA at Athene in 2019. MassMutual, Kuvare, RGA have all built variants. Aitken correctly identifies ACRA as the closest precedent here.

What is new is the application. The Standard Life vehicle puts the sidecar pattern to work on new-business UK BPA, inside a Solvency UK regulated subsidiary, with the PRA as the supervisor and the matching adjustment regime shaping the asset side. The economics work because the consortium is bringing fresh equity - not because they are exporting risk to a Bermudan reinsurer with lighter capital treatment.

The timing of the PRA’s framework is suggestive. DP2/25 was published on 14 November 2025. The Standard Life process started over a year before that, and CEO Andy Briggs flagged it at the March 2025 results. Project Ocean ran through 2025. The rebrand from Phoenix to Standard Life completed on 2 March 2026. The FT reported CVC and Prudential Financial as frontrunners in April 2026. Standard Life and its advisors will have been talking to the PRA throughout. It would be surprising if the parties and the PRA had not been in close dialogue.

What this changes about the migration argument

Three things from my previous five-thoughts piece get sharper.

It is a structural slap down to the funded-re trade. The deal does not rely on offshore funded reinsurance. As funded-re economics tighten under the PRA’s April 2026 consultation, structures like this become the alternative. DP2/25 and the funded-re consultation should be read together. They are two sides of the same regulatory move. Parochially (subject of the crown, taxpayer) I think I like that even with all the trade-offs.

The ‘bimodal’ split is happening inside listed insurers, not just between them. Last week I argued the listed sector is splitting between insurers leaning into long-duration and those exiting it. I partially regret that argument already, because Standard Life does not fit either box cleanly. The listed entity is keeping the bits of the BPA value chain the public market rewards (asset management fees, scale, distribution) and selling the bits it does not (new-business strain, long-duration spread). Aitken frames this as the listed entity reverting to a capital-light DC identity. I would put it differently. The same listed insurer is doing both halves of the bimodal split at once, in different parts of its own balance sheet. That sharpens the framing I had last week. By the way, as an aside, CEO Andy Briggs used to be at Lloyd’s Banking Group. Back 15 years ago I admired their approach to participating in the general insurance value chain, which from the outside looked like they were cherry-picking the elements that made margin and competing out the other bits. This looks a bit similar. It’s a great approach and more of the industry should do it.

It moves the migration from acquisition to co-investment. In the Apollo / Athene template, private capital owns the insurer. In the Viridium consortium template, regulated insurers own it together and pure PE is excluded. In the Standard Life template, private capital sits inside the listed insurer’s regulated subsidiary. This is a fundamentally different deal type. It changes which buyers can play (you need to live as a minority alongside a listed insurer’s operating culture). It does not avoid regulatory approval, but the approval question shifts: regulators are assessing a controlled minority-capital structure inside an incumbent insurance group, not a full transfer of an insurer to private capital. And it changes which listed insurers can attract a partner at all (only those with BPA platforms strong enough to make the terms work).

What I think happens next

The Standard Life structure becomes the template for two or three further UK listed-insurer carve-outs in the next eighteen months. Any listed UK life insurer with a scaled BPA franchise and a persistent listed-market discount has an obvious reason to consider variants. The PRA writes supervisory expectations refining how DP2/25 applies in practice. The losing bidders from Project Ocean (Blackstone, KKR, Sixth Street, BlackRock, Goldman Sachs Asset Management) regroup around the next opportunity. Five large alternative managers chasing a small number of UK BPA mandates becomes a feature of the next phase of the trade, and the price tension that creates is going to matter.

The European question I would put to readers who know continental regulatory politics better than I do. The template is now available. The political-economy alignment that makes it durable in the UK exists in different forms across the Channel. The Apollo / Athene model continues in the US, where regulators are more comfortable with full ownership and the offshore arbitrage is more durable. In the UK, I think Standard Life-style structures dominate the next phase. In continental Europe, the answer is genuinely uncertain.

There is one Aitken-flagged risk worth ending on. The 20%-plus lifetime IRRs Standard Life has been disclosing are the benchmark against which the consortium’s terms have to be judged. If the terms turn out to give the listed shareholder less than that benchmark justifies, the deal is a quiet concession that the listed market will be the wrong place to own UK BPA for the foreseeable future. The full deal terms are not public. Until they are, the structural significance of the deal is clearer than the value implications for the listed shareholder.

I am undoubtedly wrong about how the European question resolves, or which jurisdictions move first. I do not think I am wrong that this regulatory architecture satisfies prudential supervision and growth policy at the same time, making the framework more resilient than otherwise; and that there is now a worked example for any other European government that wants to engage with the same combination of pressures.